Progress in Glioma Stem Cell Research
Author:
Ramar Vanajothi1, Guo Shanchun2ORCID, Hudson BreAnna1, Liu Mingli1
Affiliation:
1. Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA 2. Department of Chemistry, Xavier University, 1 Drexel Dr., New Orleans, LA 70125, USA
Abstract
Glioblastoma multiforme (GBM) represents a diverse spectrum of primary tumors notorious for their resistance to established therapeutic modalities. Despite aggressive interventions like surgery, radiation, and chemotherapy, these tumors, due to factors such as the blood–brain barrier, tumor heterogeneity, glioma stem cells (GSCs), drug efflux pumps, and DNA damage repair mechanisms, persist beyond complete isolation, resulting in dismal outcomes for glioma patients. Presently, the standard initial approach comprises surgical excision followed by concurrent chemotherapy, where temozolomide (TMZ) serves as the foremost option in managing GBM patients. Subsequent adjuvant chemotherapy follows this regimen. Emerging therapeutic approaches encompass immunotherapy, including checkpoint inhibitors, and targeted treatments, such as bevacizumab, aiming to exploit vulnerabilities within GBM cells. Nevertheless, there exists a pressing imperative to devise innovative strategies for both diagnosing and treating GBM. This review emphasizes the current knowledge of GSC biology, molecular mechanisms, and associations with various signals and/or pathways, such as the epidermal growth factor receptor, PI3K/AKT/mTOR, HGFR/c-MET, NF-κB, Wnt, Notch, and STAT3 pathways. Metabolic reprogramming in GSCs has also been reported with the prominent activation of the glycolytic pathway, comprising aldehyde dehydrogenase family genes. We also discuss potential therapeutic approaches to GSC targets and currently used inhibitors, as well as their mode of action on GSC targets.
Subject
Cancer Research,Oncology
Reference168 articles.
1. The 2007 WHO classification of tumours of the central nervous system;Louis;Acta Neuropathol.,2007 2. Begagić, E., Pugonja, R., Bečulić, H., Čeliković, A., Tandir Lihić, L., Kadić Vukas, S., Čejvan, L., Skomorac, R., Selimović, E., and Jaganjac, B. (2023). Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings. Brain Sci., 13. 3. Angom, R.S., Nakka, N.M.R., and Bhattacharya, S. (2023). Advances in Glioblastoma Therapy: An Update on Current Approaches. Brain Sci., 13. 4. Biserova, K., Jakovlevs, A., Uljanovs, R., and Strumfa, I. (2021). Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells, 10. 5. Gisina, A., Kholodenko, I., Kim, Y., Abakumov, M., Lupatov, A., and Yarygin, K. (2022). Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. Int. J. Mol. Sci., 23.
|
|